Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


FSGS is a potentially devastating form of nephrotic syndrome. Treatment of SRNS can be difficult, especially post-transplantation. The current therapy of post-transplant SRNS includes plasmapheresis, ACE-I, CNI, and monoclonal antibodies (rituximab). Patients who are refractory to these interventions have limited therapeutic alternatives. We present a case of a patient with SRNS secondary to FSGS. He did not respond to immunosuppressive medications prior to transplant, progressed to ESRD, and was started on chronic hemodialysis. He received a DDKT which was complicated by post-transplant FSGS recurrence. A course of plasmapheresis, rituximab, and CNI were administered with some response. Ofatumumab was then given to the patient. As a result, the patient achieved partial remission. Ofatumumab may be a safe and effective option for post-transplant recurrence of FSGS.

Original languageEnglish (US)
Article numbere13413
JournalPediatric Transplantation
StatePublished - Jan 1 2019


  • FSGS
  • Ofatumumab
  • Renal Transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation


Dive into the research topics of 'Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child'. Together they form a unique fingerprint.

Cite this